Kazia Therapeutics (NASDAQ:KZIA) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, ValuEngine reports.

Separately, Zacks Investment Research downgraded shares of Kazia Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd.

Shares of KZIA stock opened at $2.43 on Tuesday. The company’s fifty day simple moving average is $2.58 and its 200-day simple moving average is $3.07. Kazia Therapeutics has a 52 week low of $2.04 and a 52 week high of $4.27. The company has a market cap of $14.80 million, a PE ratio of -2.51 and a beta of 1.52.

An institutional investor recently bought a new position in Kazia Therapeutics stock. Citadel Advisors LLC purchased a new stake in shares of Kazia Therapeutics Ltd (NASDAQ:KZIA) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 20,473 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned approximately 0.33% of Kazia Therapeutics at the end of the most recent quarter. 3.31% of the stock is owned by hedge funds and other institutional investors.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.

Recommended Story: How Investors Can Profit from Options Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.